Published in N Engl J Med on August 10, 2006
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Molecular basis of metastasis. N Engl J Med (2008) 8.19
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res (2008) 6.63
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol (2011) 4.50
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell (2009) 4.47
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res (2009) 4.02
Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A (2007) 3.92
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 3.74
How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst (2014) 3.43
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol (2011) 3.33
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell (2010) 2.86
ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A (2007) 2.85
Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst (2015) 2.81
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
GeneSigDB--a curated database of gene expression signatures. Nucleic Acids Res (2009) 2.65
A kinetic-based sigmoidal model for the polymerase chain reaction and its application to high-capacity absolute quantitative real-time PCR. BMC Biotechnol (2008) 2.60
Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun (2010) 2.54
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38
Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38
A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst (2012) 2.34
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst (2014) 2.28
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res (2010) 2.26
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26
Mechanisms of malignant progression. Carcinogenesis (2008) 2.25
MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A (2010) 2.21
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst (2014) 2.17
A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol (2006) 2.17
CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell (2009) 2.17
Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol (2011) 2.16
Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res (2006) 2.12
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09
A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One (2008) 2.09
Prostate cancer genomics: towards a new understanding. Nat Rev Genet (2008) 2.08
A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft. Kidney Int (2015) 2.02
Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol (2009) 1.91
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol (2008) 1.89
The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest (2008) 1.85
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84
Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell (2009) 1.77
Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer (2007) 1.75
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2008) 1.72
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist (2010) 1.72
Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics (2008) 1.71
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics (2011) 1.67
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res (2008) 1.66
A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell (2012) 1.65
The molecular pathology of breast cancer progression. J Pathol (2010) 1.65
Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A (2007) 1.61
Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.59
Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res (2008) 1.59
Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat (2010) 1.56
Do 'basal-like' breast cancers really exist? Nat Rev Cancer (2008) 1.55
LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res (2010) 1.55
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer (2010) 1.54
Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A (2009) 1.53
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res (2012) 1.52
Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer (2011) 1.47
Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol (2010) 1.47
Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res (2010) 1.47
The influence of feature selection methods on accuracy, stability and interpretability of molecular signatures. PLoS One (2011) 1.46
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46
Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res (2009) 1.45
Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn (2007) 1.44
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genomics (2008) 1.43
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol (2012) 1.42
Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One (2008) 1.42
The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis. BMC Med Genomics (2008) 1.41
Biomarkers in Breast Cancer - An Update. Geburtshilfe Frauenheilkd (2012) 1.41
Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst (2011) 1.38
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer (2008) 1.37
18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res (2011) 1.36
An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer. BMC Cancer (2010) 1.34
The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer (2009) 1.34
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol (2009) 1.34
The molecular profile of luminal B breast cancer. Biologics (2012) 1.33
Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. BMC Bioinformatics (2010) 1.33
Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer (2013) 1.33
Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. J Clin Oncol (2010) 1.33
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics (2011) 1.32
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell (2002) 17.32
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. Nature (2008) 10.95
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
A custom microarray platform for analysis of microRNA gene expression. Nat Methods (2004) 9.44
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res (2008) 7.39
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
Molecular maps of the reorganization of genome-nuclear lamina interactions during differentiation. Mol Cell (2010) 6.71
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Deconstructing the molecular portraits of breast cancer. Mol Oncol (2010) 5.37
Adjustment of systematic microarray data biases. Bioinformatics (2004) 5.22
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A (2003) 4.47
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res (2007) 4.41
Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinformatics (2005) 4.27
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet (2006) 3.96
Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell (2004) 3.91
Common markers of proliferation. Nat Rev Cancer (2006) 3.85
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
ChIPOTle: a user-friendly tool for the analysis of ChIP-chip data. Genome Biol (2005) 3.83
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 3.83
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res (2008) 3.80
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol (2007) 3.32
Molecular portraits and the family tree of cancer. Nat Genet (2002) 3.28
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell (2008) 3.25
Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet (2006) 3.19
Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04
Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res (2003) 3.02
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res (2006) 2.95
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res (2009) 2.84
Determination of stromal signatures in breast carcinoma. PLoS Biol (2005) 2.84
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 2.74
Statistical modeling for selecting housekeeper genes. Genome Biol (2004) 2.73
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res (2005) 2.73
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A (2008) 2.64
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
Gene expression patterns associated with p53 status in breast cancer. BMC Cancer (2006) 2.61
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38
A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One (2009) 2.29
On the organization of bioinformatics core services in biology-based research institutes. Bioinformatics (2011) 2.29
RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat (2011) 2.23
FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clin Cancer Res (2007) 2.22
CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell (2009) 2.17
Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol (2009) 2.17
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res (2010) 2.15
MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet (2007) 2.14
Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol (2007) 2.12
A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics (2005) 2.08
Constitutive nuclear lamina-genome interactions are highly conserved and associated with A/T-rich sequence. Genome Res (2012) 2.04
Mammary development meets cancer genomics. Nat Med (2009) 2.04